A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab Era
NCT04624971 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000
Last updated 2020-11-12
Summary
The purpose of this study is to determine the predictive value of a model of Nomogram Prognostic Index (NPI) in patients with Diffuse Large B cell lymphoma.
Conditions
Sponsors & Collaborators
-
Sun Yat-sen University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-11-30
- Primary Completion
- 2020-11-30
- Completion
- 2020-11-30
Countries
- China
Study Locations
More Related Trials
-
A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
NCT05615974 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma
NCT05348213 ·Status: RECRUITING ·Phase: PHASE2
-
A Retrospective Study on Extranodal DLBCL
NCT06549361 ·Status: COMPLETED
-
Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
NCT00568815 ·Status: COMPLETED ·Phase: PHASE2
-
Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies
NCT04994626 ·Status: UNKNOWN ·Phase: PHASE2
-
A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma
NCT05506410 ·Status: RECRUITING
-
Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults
NCT01809600 ·Status: COMPLETED
-
A Retrospective Cohort Study: Influence of MTHFR C677T and A1298C Polymorphisms on the Survival of Pediatric Patients With Non-Hodgkin's Lymphoma
NCT04469543 ·Status: COMPLETED
-
Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma
NCT04425824 ·Status: UNKNOWN ·Phase: PHASE2
-
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
NCT07200375 ·Status: RECRUITING
-
The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
NCT06656234 ·Status: NOT_YET_RECRUITING
-
The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Lymphomas
NCT03000738 ·Status: UNKNOWN
-
Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma
NCT06846489 ·Status: RECRUITING ·Phase: PHASE2
-
Non-invasive Tumor Immunoglobulin Gene Next Generation Sequencing (IgNGS) in Diffuse Large B Cell Lymphoma (DLBCL)
NCT04237168 ·Status: UNKNOWN
-
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
NCT06651853 ·Status: RECRUITING ·Phase: PHASE2
-
Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma
NCT04432402 ·Status: UNKNOWN ·Phase: NA
-
JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma
NCT06045585 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
NCT07255963 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors
NCT02929615 ·Status: UNKNOWN ·Phase: PHASE4
-
A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT02957019 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
NCT01340443 ·Status: COMPLETED
-
Translational Study of Molecular Classification of Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05318391 ·Status: COMPLETED
-
Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma
NCT02474550 ·Status: UNKNOWN
-
Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab
NCT05267054 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
NCT07189065 ·Status: RECRUITING ·Phase: PHASE2